Table 1 Baseline clinical characteristics
| Patient characteristic |
DP group (n = 103) |
S-1 group (n = 72) | p value |
|---|---|---|---|
| Age (median, year) | 62 | 64 | 0.647 |
| < 60 | 48 (46.6%) | 31 (43.1%) | |
| ≥ 60 | 55 (53.4%) | 41 (56.9%) | |
| Gender | 0.873 | ||
| Male | 65 (63.1%) | 47 (65.3%) | |
| Female | 38 (36.9%) | 25 (34.7%) | |
| KPS | 0.756 | ||
| 90 | 43 (41.7%) | 28 (38.9%) | |
| ≥ 70 | 60 (58.3%) | 44 (61.1%) | |
| Tumor location | 0.394 | ||
| Upper third | 28 (27.2%) | 16 (22.2%) | |
| Middle third | 60 (58.3%) | 40 (55.6%) | |
| Lower third | 15 (14.5%) | 16 (22.2%) | |
| Primary tumor length (cm) | 0.759 | ||
| < 5 | 56 (54.4%) | 41 (56.9%) | |
| ≥ 5 | 47 (45.6%) | 31 (43.1%) | |
| Smoking | 0.273 | ||
| Nonsmoker | 43 (41.7%) | 24 (33.3%) | |
| Smoker | 60 (58.3%) | 48 (66.7%) | |
| Drinking | 0.358 | ||
| No | 49 (47.6%) | 29 (40.3%) | |
| Yes | 54 (52.4%) | 43 (59.7%) | |
| Differentiation | 0.838 | ||
| Well | 14 (13.6%) | 8 (11.1%) | |
| Moderate | 59 (57.3%) | 44 (61.1%) | |
| Poor | 30 (29.1%) | 20 (27.7%) | |
| Clinical T stage | 1.000 | ||
| No invasion to adjacent organs | 56 (54.4%) | 39 (54.2%) | |
| Invasion to adjacent organs | 47 (45.6%) | 33 (45.8%) | |
| Clinical N stage | 0.867 | ||
| N0 | 30 (29.1%) | 20 (27.8%) | |
| N1 | 73 (70.9%) | 52 (72.2%) | |
| Reason for no surgery | 0.924 | ||
| Patient refusal | 8 (7.7%) | 6 (8.3%) | |
| Surgical contraindication | 15 (14.6%) | 9 (12.5%) | |
| Unresectable disease | 65 (63.1%) | 44 (61.1%) | |
| Unknown | 15 (14.6%) | 13 (18.1%) | |
| Radiation dose (Gy) | 0.698 | ||
| 50 | 34 (33.0%) | 23 (31.9%) | |
| 50.4 | 46 (44.7%) | 29 (40.3%) | |
| > 50.4 | 23 (22.3%) | 20 (27.8%) | |
| Radiotherapy techniques | 0.410 | ||
| 3D-CRT | 30 (29.1%) | 26 (36.1%) | |
| IMRT | 73 (70.9%) | 46 (63.9%) | |
| Consolidation chemotherapy | 0.537 | ||
| Yes | 61 (59.2%) | 39 (54.2%) | |
| No | 42 (40.8%) | 33 (45.8%) | |
| Nutritional support | 0.265 | ||
| Yes | 17 (16.5%) | 7 (9.7%) | |
| No | 86 (83.5%) | 65 (90.3%) |